📊 COYA Key Takeaways
Is Coya Therapeutics, Inc. (COYA) a Good Investment?
Coya Therapeutics is a pre-commercial pharmaceutical company burning through cash with severe operating losses and negative margins, though revenue growth of 124% YoY suggests product traction. The company maintains adequate liquidity with $46.8M in cash and minimal debt, but at the current burn rate of $10.7M in operating cash flow losses, runway is limited to approximately 4-5 years without achieving profitability or securing additional financing. Investment viability depends entirely on clinical success and commercialization of pipeline candidates to reverse deeply negative unit economics.
Coya Therapeutics shows strong balance-sheet quality for a clinical-stage biotech, with $46.82M of cash, no meaningful debt, and very high liquidity. Revenue growth was sharp, but profitability remains deeply negative, with operating margin of -283.9% and free cash flow of -$10.74M, indicating the business is still heavily dependent on external funding or future commercialization success. Fundamentally, this is a financially stable but still highly speculative company where cash runway and the durability of revenue growth matter more than current earnings.
Why Buy Coya Therapeutics, Inc. Stock? COYA Key Strengths
- Exceptional revenue growth of 123.6% YoY indicates emerging commercial traction and market adoption
- Strong balance sheet with $46.8M cash, minimal debt (0.00x Debt/Equity), and 8.50x current ratio providing substantial financial flexibility
- Adequate liquidity runway of approximately 4-5 years based on current cash position and operating burn rate
- Very strong liquidity, with 8.50x current and quick ratios supported by $46.82M in cash
- Debt-free balance sheet and modest liabilities relative to $43.03M in equity
- Revenue grew 123.6% YoY, showing improving top-line traction
COYA Stock Risks: Coya Therapeutics, Inc. Investment Risks
- Severe operating losses of -$22.6M on only $7.9M revenue with -283.9% operating margin indicate unsustainable unit economics and pre-profitability status
- Negative free cash flow of -$10.7M annually demonstrates the company is not cash generative and remains dependent on capital reserves
- No long-term debt disclosure combined with pharmaceutical sector dynamics suggest future financing needs are likely required before achieving profitability
- Diluted EPS of -$1.27 reflects substantial shareholder dilution, with 9 Form 4 insider filings in 90 days warranting monitoring for capital raising activities
- Extremely weak profitability, with -283.9% operating margin and -267.1% net margin
- Negative operating cash flow and free cash flow indicate ongoing cash burn
- Revenue quality may be less durable if driven by partnership or non-recurring sources rather than broad commercial operations
Key Metrics to Watch
- Operating cash flow trend and path to breakeven timeline
- Quarterly revenue growth sustainability and gross margin realization
- Cash balance depletion rate relative to milestone achievements
- Clinical trial progress and regulatory approval status of pipeline candidates
- Insider buying/selling patterns and capital raising announcements
- Quarterly operating cash burn relative to cash balance
- Revenue consistency and progress toward narrower operating losses
Coya Therapeutics, Inc. (COYA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.50x current ratio provides a solid financial cushion.
COYA Profit Margin, ROE & Profitability Analysis
COYA vs Healthcare Sector: How Coya Therapeutics, Inc. Compares
How Coya Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Coya Therapeutics, Inc. Stock Overvalued? COYA Valuation Analysis 2026
Based on fundamental analysis, Coya Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Coya Therapeutics, Inc. Balance Sheet: COYA Debt, Cash & Liquidity
COYA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Coya Therapeutics, Inc.'s revenue has grown significantly by 32% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.98 indicates the company is currently unprofitable.
COYA Revenue Growth, EPS Growth & YoY Performance
COYA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $3.6M | -$2.1M | $-0.13 |
| Q2 2025 | $163.6K | -$2.9M | $-0.19 |
| Q1 2025 | $126.8K | -$5.1M | $-0.35 |
| Q3 2024 | N/A | -$2.7M | $-0.26 |
| Q2 2024 | N/A | -$2.7M | $-0.19 |
| Q1 2024 | N/A | -$2.7M | $-0.28 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Coya Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
COYA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Coya Therapeutics, Inc. (CIK: 0001835022)
📋 Recent SEC Filings
❓ Frequently Asked Questions about COYA
What is the AI rating for COYA?
Coya Therapeutics, Inc. (COYA) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are COYA's key strengths?
Claude: Exceptional revenue growth of 123.6% YoY indicates emerging commercial traction and market adoption. Strong balance sheet with $46.8M cash, minimal debt (0.00x Debt/Equity), and 8.50x current ratio providing substantial financial flexibility. ChatGPT: Very strong liquidity, with 8.50x current and quick ratios supported by $46.82M in cash. Debt-free balance sheet and modest liabilities relative to $43.03M in equity.
What are the risks of investing in COYA?
Claude: Severe operating losses of -$22.6M on only $7.9M revenue with -283.9% operating margin indicate unsustainable unit economics and pre-profitability status. Negative free cash flow of -$10.7M annually demonstrates the company is not cash generative and remains dependent on capital reserves. ChatGPT: Extremely weak profitability, with -283.9% operating margin and -267.1% net margin. Negative operating cash flow and free cash flow indicate ongoing cash burn.
What is COYA's revenue and growth?
Coya Therapeutics, Inc. reported revenue of $7.9M.
Does COYA pay dividends?
Coya Therapeutics, Inc. does not currently pay dividends.
Where can I find COYA SEC filings?
Official SEC filings for Coya Therapeutics, Inc. (CIK: 0001835022) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is COYA's EPS?
Coya Therapeutics, Inc. has a diluted EPS of $-1.27.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is COYA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Coya Therapeutics, Inc. has a SELL rating with 80% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is COYA stock overvalued or undervalued?
Valuation metrics for COYA: ROE of -49.3% (sector avg: 15%), net margin of -267.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy COYA stock in 2026?
Our dual AI analysis gives Coya Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is COYA's free cash flow?
Coya Therapeutics, Inc.'s operating cash flow is $-10.7M, with capital expenditures of N/A. FCF margin is -135.2%.
How does COYA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -267.1% (avg: 12%), ROE -49.3% (avg: 15%), current ratio 8.50 (avg: 2).